Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).

Abstract

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

• Authors: Julie Boucau, Rockib Uddin, Caitlin Marino, James Regan, James P Flynn, Manish C Choudhary, Geoffrey Chen, Ashley M Stuckwisch, Josh Mathews, May Y Liew, Arshdeep Singh, Zahra Reynolds, Surabhi L Iyer, Grace C Chamberlin, Tammy D Vyas, Jatin M Vyas, Sarah E Turbett, Jonathan Z Li, Jacob E Lemieux, Amy K Barczak, Mark J Siedner
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 76 Issue 3 Pg. e526-e529 (02 08 2023) ISSN: 1537-6591 [Electronic] United States
• PMID: 35737946 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• nirmatrelvir
• Ritonavir

Topics

• Humans
• COVID-19
• COVID-19 Drug Treatment
• Ritonavir (therapeutic use)
• Mutation